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Abstract Currently a central question that remains unresolved
is the potential importance of phospholipase C (PLC)-Q1 in cell
mitogenesis. In this study, we introduced wild-type PLC-Q1
plasmid and mutants Y771F and Y783F into CCL-39 fibroblasts
and investigated their effect on host cell functions. To our
surprise, Y771F and Y783F plasmids appeared to have opposite
effects on CCL-39 cell actin-cytoskeleton organization and cell
proliferation. Y771F transfectants increased cell proliferation by
two-fold. Y783F transfectants showed much thicker actin
filaments and decreased cell growth rate by 50%. These results
suggest that PLC-Q1 mutations have an essential impact on cell
mitogenesis.
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1. Introduction
A variety of growth factors, such as platelet-derived growth
factor (PDGF) and epidermal growth factor (EGF), promote
an increased turnover of inositol phospholipids in ¢broblasts,
transformed cells and some tissues. Stimulation of speci¢c
receptors by these growth factors triggers phospholipase C
(PLC)-Q1 tyrosine phosphorylation and the hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) with production
of two important secondary messengers, diacylglycerol and
inositol 1,4,5-trisphosphate [1,2]. Recently, some G protein-
coupled receptor agonists were also found to induce PLC-Q1
tyrosine phosphorylation by non-receptor tyrosine kinases.
These agonists include angiotensin II [3,4], thrombin [5], ad-
enosine triphosphate (ATP) [6], and lysophosphatic acid (Pei,
Z.-D. and Williamson, J.R., unpublished observation). The
major sites of tyrosine phosphorylation in PLC-Q1 were iden-
ti¢ed to be at Tyr771, Tyr783 and Tyr1254 [1]. The role of PLC-
Q1 tyrosine phosphorylation in its activation has been studied
by substituting Phe for Tyr at the three sites Tyr771, Tyr783,
and Tyr1254. It was found that Tyr783 phosphorylation was
essential for PLC-Q1 activation in vivo, although it was not
in vitro [7]. In contrast, Tyr771 mutation was found to increase
PLC-Q1 enzymatic activity [7].
The role of PLC-Q1 in cell mitogenesis is still not clear [8].
Early studies suggested that PLC-Q1 might have little e¡ect on
cell mitogenesis. However, recent studies have provided evi-
dence against this view. Microinjection studies indicated that
PLC-Q1 could induce DNA synthesis [9^11]. PLC-Q1 was also
found to be involved in nerve growth factor and PDGF-in-
duced cell mitogenesis [12^17]. Furthermore, a more recent
report indicated that PLC-Q1 might be essential in embryonal
development [18].
In the present study, the e¡ect of Tyr771 and Tyr783 muta-
tions on cell function was investigated. Introduction of Tyr771
mutant into CCL-39 ¢broblasts increased the host cell growth
rate. In contrast, Tyr783 mutation caused morphology changes
and an inhibition of cell growth in host cells.
2. Materials and methods
2.1. Materials
The plasmids that encode wild-type (WT) PLC-Q1, mutants Y771F
and Y783F and their expression vector pMJ30 [7], and the monoclo-
nal antibody against PLC-Q1 were kindly provided by Dr. S.G. Rhee
(National Institute of Health, Bethesda, MD, USA). The monoclonal
antibody against the extracellular signal-regulated kinase 2 (ERK2),
the mouse IgG, and protein A/G plus agarose beads were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The
monoclonal antibody against phosphotyrosine was purchased from
Transduction Laboratories (Lexington, KY, USA). The BB dimeric
form of PDGF was from Upstate Biotechnology (Lake Placid, NY,
USA).
2.2. Cell culture
CCL-39 cells, which are derived from Chinese hamster lung ¢bro-
blasts, were purchased from American Type Culture Collection
(Rockville, MD, USA) and maintained at 37‡C in a humidi¢ed 5%
CO2 atmosphere in McCoy’s 5A medium (Life Technologies, Inc.,
Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum.
For cell stimulation experiments, cells were grown to 80% con£uence
and starved for 20 h in the maintaining medium without serum.
2.3. Transfection
Plasmid DNAs were prepared by Wizard Plus Maxipreps DNA
Puri¢cation System from Promega (Madison, WI, USA). For stable
transfection, plasmid DNAs were introduced into CCL-39 cells by a
liposome-mediated electroporation method as described in ref. [19]. In
this study, the cells were electroporated at 180 V, 700 WF using BTX
Electro Cell Manipulator 600 (Genetronics, Inc., San Diego, CA,
USA).
2.4. Actin ¢lament visualization by £uorescence staining
Cells were grown to subcon£uency on coverslips and were ¢xed
with 3.7% formaldehyde in phosphate-bu¡ered saline (PBS) for 1 h
on ice, permeabilized with cold 10% DMSO for 5 min, and labeled for
1 h at room temperature with 0.1 Wg/ml FITC-labeled phalloidine
(Sigma) in 10% MeOH/PBS. Cells were viewed on a Nikon micro-
scope with an FITC ¢lter and photographed with Kodak T-MAX 400
¢lm.
2.5. Cell growth determination
Cells were seeded in quartets in 100-mm petri dishes at a cell density
of 5U104/dish. Cell numbers were determined daily by mixing with
0.1% trypan blue dye and counted on a hemocytometer.
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2.6. Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting techniques were de-
scribed elsewhere [4].
2.7. Mitogen-activated protein kinase (MAPK) gel shift assay
Cells in 100-mm tissue culture plates were stimulated with 30 ng/ml
of PDGF or vehicle for 5 min. The stimulation was terminated by
washing with 10 ml PBS, and the cells were lysed in lysis bu¡er
containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% deoxy-
cholic acid, 1% NP-40, 10% glycerol, 50 mM NaF with 10 Wg/ml
leupeptin and aprotinin, 1 mM phenylmethylsulfonyl £uoride and
1 mM Na3VO4 for 30 min on ice. 200 Wg of cell lysate from each
cell line was used for immunoprecipitation with 1 Wg of anti-ERK2
serum. The immunoprecipitates were analyzed by 12% SDS polyacryl-
amide gel and immunoblotted with anti-ERK2 antibodies.
3. Results
CCL-39 cells have relatively low levels of endogenous PLC-
Q1 (data not shown). They were transfected with WT PLC-Q1,
mutants Y771F and Y783F, and the vector plasmid pMJ30,
along with the selection marker plasmid pSV2-neo. After
transfection, cells were selected in cell growth medium con-
taining 0.5 mg/ml G418 (Sigma). G418-resistant colonies were
isolated and expanded into independent cell lines. These cell
lines were ¢rst screened for the expression of PLC-Q1. Fig. 1
shows PLC-Q1 expression in cells transfected respectively by
WT-PLC-Q1 plasmid (lane 2, colony #2), Y771F plasmid (lane
3, colony #5) and Y783F plasmid (lane 4, colony #3). They
all had a higher expression level of PLC-Q1 than the vector
transfectant (lane 1, colony #7). These transfectants were used
for later studies.
One of the surprising ¢ndings observed with these trans-
fectants was that Y783F transfectants showed a di¡erent mor-
phology from the transfectants by WT PLC-Q1 and Y771F
plasmids. As shown in Fig. 2, the CCL-39 cells transfected
by WT PLC-Q1 and Y771F plasmids appeared to be very
similar to those vector-transfected cells in actin-cytoskeleton
organization. However, the Y783F transfectants formed much
thicker stress ¢bers, and the cell morphology appeared to be
more expanded (Fig. 2D). About 90% of Y783F-transfected
colonies showed this type of morphology, as did a repeat of
the stable transfection.
The transfectants were further studied for an assessment of
cell proliferation. Interestingly, cells containing the Y771F
plasmid almost doubled the cell growth rate, while WT
PLC-Q1 plasmid did not show much e¡ect (Fig. 3). In con-
trast, Y783F plasmid inhibited cell proliferation by about 50%
(Fig. 3).
These transfectants were further characterized by measuring
PLC-Q1 tyrosine phosphorylation and MAPK/ERK2 activa-
tion. The cells were stimulated with PDGF for 1 min and cell
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Fig. 1. Transfection and PLC-Q1 expression. 10 Wg of WP PLC-Q1,
Y771F, Y783F and the vector pMJ30 plasmid DNAs, along with
0.5 Wg of pSV2neo plasmid DNA, were introduced into CCL-39
cells by electroporation [19]. Independent cell lines were established
from individual G418-resistant colonies. To determine PLC-Q1 ex-
pression, cells were collected from 100-mm petri dishes and lysed as
described in ref. [4]. Equal amounts of proteins were loaded onto
10% SDS polyacrylamide gel and blotted with PLC-Q1 monoclonal
antibody.
Fig. 2. Y783F plasmid induced actin reorganization in CCL-39 cells. Cells were seeded on coverslips, ¢xed and stained as described in Section
2. A: Vector #7; B: WT-PLC-Q1 #2; C: Y771F #5; D: Y783F #3.
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lysates were immunoprecipitated (IP) with anti-PLC-Q1 anti-
body and blotted with anti-phosphotyrosine antibody. As
shown in Fig. 4, the intensity of PLC-Q1 tyrosine phosphoryl-
ation in each cell line was directly correlated with the expres-
sion level of PLC-Q1. These results suggest that mutations at
Tyr771 and Tyr783 do not have much e¡ect on total PLC-Q1
tyrosine phosphorylation.
Since Y771F and Y783F transfectants showed altered cell
proliferation rates (Fig. 3), we wondered whether these trans-
fectants showed any di¡erence in MAPK/ERK2 activity from
the vector transfectant. The cells were stimulated with PDGF
for 5 min, and MAPK phosphorylation (which is correlated
with MAPK activation) was studied by the gel shift assay.
The Y771F transfectant was found to be much more activated
than vector-transfected cells (Fig. 5), which is consistent with
the results in Fig. 3 that the Y771F transfectant had a higher
growth rate. However, the Y783F transfectant did not show
decreased MAPK activation (Fig. 5), although their growth
rate was about 50% less than vector-transfected cells (Fig. 3).
EGF stimulation gave similar results (data not shown).
4. Discussion
The substrate for PLC-Q1, PIP2, is a membrane lipid, and
has been suggested to be a regulator of actin ¢lament reor-
ganization. PIP2 binds to actin-regulatory proteins such as
pro¢lin, co¢lin, gelsolin, gCap, and K-actinin, and therefore
regulates actin polymerization and depolymerization [20]. It is
proposed that PIP2 promotes actin polymerization, while de-
creased levels of PIP2 together with increased cytosolic Ca2
favors actin depolymerization [21]. In the current study, we
demonstrate that PLC-Q1 mutation at Tyr783, which was
shown to be essential for PLC-Q1 activation in vivo [7], could
actually induce CCL-39 cells to form much thicker actin ¢la-
ment bundles (Fig. 2). This result is consistent with the hy-
pothesis that PIP2 accumulation promotes actin polymeriza-
tion.
Another ¢nding of interest in this study was that Y771F
and Y783F plasmids showed opposite e¡ects on CCL-39 cell
proliferation. In the colonies we studied, Y771F increased cell
proliferation by about 50% but Y783F inhibited cell growth
by 50% (Fig. 3). The WT PLC-Q1 plasmid showed no signi¢-
cant e¡ect on host cell proliferation, which is consistent with a
previous report [22]. Y771F plasmid was previously found to
increase PLC-Q1 enzymatic activity in vivo [7]. Therefore, the
Y771F plasmid-induced higher growth rate in CCL-39 cells is
possibly due to an increased enzymatic activity. Interestingly,
the Y771F transfectant also showed a more activated MAPK/
ERK2 in response to PDGF stimulation (Fig. 5), which in-
dicates that Y771F-induced cell growth might be through the
MAPK pathway.
The Y783F transfectant showed inhibited cell growth, but
the ERK2 activation was not less than the vector and WT
PLC-Q1 transfectants (Fig. 5). The reason is possibly due to
the altered actin structure in Y783F transfectants. Cell actin
organization has been correlated with the cell proliferation,
but how this is achieved is not known. From our current
results, actin may a¡ect cell proliferation by promoting a
MAPK independent pathway, or perhaps by interrupting
cell signaling downstream of ERK2.
Our current studies provide a new insight on how PLC-Q1
may a¡ect cell mitogenesis. Tyr771 is a potential site that may
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Fig. 3. Y771F and Y783F plasmids had opposite e¡ects on cell pro-
liferation in CCL-39 cells. Cells were equally seeded at day 1 in cell
growth medium and cell numbers were then determined by hemocy-
tometer for 4 consecutive days.
Fig. 4. PLC-Q1 tyrosine phosphorylation induced by PDGF. Cells
were starved overnight and stimulated with 30 ng/ml PDGF for
1 min, and cell lysates were immunoprecipitated (IP) with the PLC-
Q1 monoclonal antibody. The immunoprecipitates were separated by
10% SDS polyacrylamide gel and blotted with anti-phosphotyrosine
and anti-PLC-Q1 antibodies, respectively.
Fig. 5. MAPK activation induced by PDGF. Serum-starved trans-
fected cells were stimulated with 30 ng/ml PDGF for 5 min, and
cell lysates were immunoprecipitated with anti-ERK2 serum. The
immunoprecipitates were separated by 12% SDS polyacrylamide gel
and blotted with ERK2 monoclonal antibody.
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cause cell-transforming phenotype. Mutation at Tyr783 seems
to do just the opposite, which may be used to reverse cell-
transforming phenotype or to induce cell apoptosis. The ¢nd-
ing that Tyr783 mutation promotes actin polymerization sug-
gests that PLC-Q1 may also be linked to signaling pathways
like the Rho GTPase pathway or the integrin-mediated path-
way.
Acknowledgements: The authors thank Dr. Sue Goo Rhee for the
PLC-Q1 plasmids and the anti-PLC-Q1 antibody. This work was sup-
ported in part by National Institute of Health Grants DK-15120 and
DK-07314.
References
[1] Rhee, S.G. and Bae, Y.S. (1997) J. Biol. Chem. 272, 15045^
15048.
[2] Schlessinger, J. (1997) Proc. Natl. Acad. Sci. USA 94, 2798^2799.
[3] Marrero, M.B., Paxton, W.G., Du¡, J.L., Berk, B.C. and Bern-
stein, K.E. (1994) J. Biol. Chem. 269, 10935^10939.
[4] Pei, Z., Maloney, J.A., Yang, L. and Williamson, J.R. (1996)
Arch. Biochem. Biophys. 345, 103^110.
[5] Rao, G.N., Delafontaine, P. and Runge, M.S. (1995) J. Biol.
Chem. 270, 27871^27875.
[6] Puceat, M. and Vassort, G. (1996) Biochem. J. 318, 723^728.
[7] Kim, H.K., Kim, J.W., Zilberstein, A., Margolis, B., Kim, J.G.,
Schlessinger, J. and Rhee, S.G. (1991) Cell 65, 435^441.
[8] Kamat, A. and Carpenter, G. (1997) Cytokine Growth Factor
Rev. 8, 109^117.
[9] Smith, M.R., Liu, Y.-L., Kim, H., Rhee, S.G. and Kung, H.-F.
(1990) Science 247, 1074^1077.
[10] Huang, P.S., Davis, L., Huber, H., Goodhart, P.J., Wegrzyn,
R.E., Oli¡, A. and Heimbrook, D.C. (1995) FEBS Lett. 358,
287^292.
[11] Smith, M.R., Liu, Y., Kim, S.R., Bae, Y.S., Kim, C.G., Kwon,
K.-S., Rhee, S.G. and Kung, H.-F. (1996) Biochem. Biophys.
Res. Commun. 222, 186^193.
[12] Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T.,
Greene, L.A. and Kaplan, D.R. (1994) Neuron 12, 691^705.
[13] Valius, M. and Kazlauskas, A. (1993) Cell 73, 321^334.
[14] Valius, M., Secrist, J.P. and Kazlauskas, A. (1995) Mol. Cell
Biol. 15, 3058^3071.
[15] Roche, S., McGlade, J., Jones, M., Gish, G.D., Pawson, T. and
Courtneidge, S.A. (1996) EMBO J. 15, 4940^4948.
[16] DeMali, K.A., Whiteford, C.C., Ulug, E.T. and Kazlauskas, A.
(1997) J. Biol. Chem. 272, 9011^9018.
[17] Alimandi, M., Heidaran, M.A., Gutkind, J.S., Zhang, J., Ell-
more, N., Valius, M., Kazlauskas, A., Pierce, J.H. and Li, W.
(1997) Oncogene 15, 585^593.
[18] Ji, Q.-S., Winnier, G.E., Niswender, K.D., Horstman, D.W.,
Wisdom, R., Magnuson, M.A. and Carpenter, G. (1997) Proc.
Natl. Acad. Sci. USA 94, 2999^3003.
[19] Pei, Z., Calmels, T.P.G., Creutz, C.E. and Sebti, S.M. (1995)
Mol. Pharmacol. 48, 676^681.
[20] Sakisaka, T., Itoh, T., Miura, K. and Takenawa, T. (1997) Mol.
Cell Biol. 17, 3841^3849.
[21] Lee, S.B. and Rhee, S.G. (1995) Curr. Opin. Cell Biol. 7, 183^
189.
[22] Margolis, B., Zilbersein, A., Franks, C., Felder, S., Kremer, S.,
Ullrich, A., Rhee, S.G., Skorecki, K. and Schlessinger, J. (1990)
Science 248, 607^610.
FEBS 19831 17-2-98
Z.-D. Pei, J.R. Williamson /FEBS Letters 423 (1998) 53^5656
